


The Fund's investment objective is to provide an above average yield together with capital growth by investing predominantly in the UK.
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline | 6.7% |
| Vodafone Group | 5.7% |
| Royal Dutch Shell B | 5.3% |
| British American Tobacco | 4.9% |
| BP | 4.3% |
| AstraZeneca | 3.6% |
| Imperial Tobacco Group | 3.3% |
| Unilever | 3.1% |
| Aberforth UK Small Companies | 2.5% |
| Reckitt Benckiser Group | 2.4% |
| Key | % Net Assets |
|---|---|
| 6.7% | |
| 5.7% | |
| 5.3% | |
| 4.9% | |
| 77.4% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 902.80p |
| Currency | GBP |
| Change | 1.00p |
| % | 0.11% |
| YTD change | 101.60p |
| YTD % | 12.68% |
| Fund Inception | 16/07/1975 |
|---|---|
| Fund Manager | HSBC Multimanager |
| TER | 1.65 (15-Jan-2012) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | £500 |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | 4.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.06 |
You are here: research